Biohit: Sustainability of turnaround being tested
Inderes
Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period. We feel a permanent turnaround of the result is likely thanks to new products, the renewed Chinese distribution agreement and effective implementation of the strategy. We believe that the development of new products and successful commercialization are key to the company's long-term success.
Login required
This content is only available for logged in users
Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures30.06.2023
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 11.0 | 11.3 | 12.6 |
| growth-% | 17.0 % | 3.2 % | 11.5 % |
| EBIT (adj.) | 1.1 | 1.2 | 1.6 |
| EBIT-% (adj.) | 10.3 % | 10.9 % | 12.4 % |
| EPS (adj.) | 0.04 | 0.07 | 0.09 |
| Dividend | 0.00 | 0.00 | 0.05 |
| Dividend % | 1.9 % | ||
| P/E (adj.) | 39.3 | 38.3 | 29.0 |
| EV/EBITDA | 11.4 | 19.5 | 15.8 |
Forum discussions
